Neuroinflammation, Stem Cells, and Stroke

Stroke. 2022 May;53(5):1460-1472. doi: 10.1161/STROKEAHA.121.036948. Epub 2022 Apr 5.

Abstract

Stroke remains a significant unmet clinical need with few treatment options that have a very narrow therapeutic window, thereby causing massive mortality and morbidity in the United States and around the world. Accordingly, finding safe and effective novel treatments with a wider therapeutic window stands as an urgent need in stroke. The progressive inflammation that occurs centrally and peripherally after stroke serves as a unique therapeutic target to retard and even halt the secondary cell death. Stem cell therapy represents a potent approach that can diminish inflammation in both the stroke brain and periphery (eg, spleen), advancing a paradigm shift from a traditionally brain-focused therapy to treating stroke as a neurological disorder with a significant peripheral pathology. The purpose of this review article is to highlight the inflammation-mediated secondary cell death that plagues both brain and spleen in stroke and to evaluate the therapeutic potential of stem cell therapy in dampening these inflammatory responses.

Keywords: blood-brain barrier; central nervous system; hemorrhage; inflammation; interleukin.

Publication types

  • Review
  • Research Support, N.I.H., Extramural

MeSH terms

  • Humans
  • Inflammation / etiology
  • Inflammation / therapy
  • Neuroinflammatory Diseases*
  • Stem Cell Transplantation
  • Stroke* / complications
  • United States